文献速递淋巴瘤

晚期霍奇金淋巴瘤大淋巴结肿块在ABVD后完全代谢缓解可安全省略巩固放疗:GITIL/FIL HD0607随机试验最终分析

Consolidation Radiotherapy Could Be Safely Omitted in Advanced Hodgkin Lymphoma With Large Nodal Mass in Complete Metabolic Response After ABVD: Final Analysis of the Randomized GITIL/FIL HD0607 Trial.
PubMed 文献 · J Clin Oncol · 2020-09-18

HD0607试验纳入晚期霍奇金淋巴瘤且基线有大淋巴结肿块(≥5 cm)、ABVD两周期和六周期后PET均阴性的患者,随机接受巩固放疗或不进一步治疗。中位随访5.9年,各肿块大小亚组的6年无进展生存率在巩固放疗与不治疗间均无显著差异,提示可安全省略巩固放疗。

要点

  • 基线大淋巴结肿块(≥5 cm)且PET-2和PET-6均阴性的晚期霍奇金淋巴瘤患者可安全省略巩固放疗。
  • 巩固放疗中位剂量30.6 Gy(范围24-36 Gy),各亚组6年无进展生存率与不治疗组无显著差异。
  • 省略巩固放疗的结论不受基线大淋巴结肿块大小影响。

核心结论

  • 对于基线有大淋巴结肿块且PET-2和PET-6均阴性的晚期霍奇金淋巴瘤患者,可安全省略巩固放疗,不受基线肿块大小影响。

研究设计与样本

  • HD0607随机试验纳入晚期(IIB-IVB)霍奇金淋巴瘤患者,基线有大淋巴结肿块(最大直径≥5 cm)且ABVD两周期和六周期后PET均阴性,随机接受巩固放疗或不进一步治疗。
  • 共296例随机分组患者,基线肿块最大直径5-7 cm者101例(34%,亚组A),8-10 cm者96例(32%,亚组B),经典巨块(>10 cm)者99例(33%,亚组C)。

关键数值与推荐

  • 大淋巴结肿块定义为基线最大直径≥5 cm。
  • 巩固放疗中位剂量30.6 Gy(范围24-36 Gy)。

临床怎么用

  • 对ABVD后PET-2和PET-6均阴性的晚期霍奇金淋巴瘤伴基线大淋巴结肿块患者,可考虑省略巩固放疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the role of consolidation radiotherapy (cRT) in advanced-stage Hodgkin lymphoma (HL) presenting at baseline with a large nodal mass (LNM) in complete metabolic response after doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapy. PATIENTS AND METHODS: Advanced-stage (IIB-IVB) HL patients, enrolled in the HD 0607 trial (Clinicaltrial.gov identifier NCT00795613), with both a negative PET after two (PET-2) and six (PET-6) ABVD cycles, who presented at baseline with an LNM, defined as a nodal mass with the largest diameter ≥ 5 cm, were prospectively randomly assigned to receive cRT over the LNM or no further treatment (NFT). RESULTS: Among 296 randomly assigned patients, the largest diameter of LNM at baseline was 5-7 cm in 101 (34%; subgroup A) and 8-10 cm in 96 (32%; subgroup B), whereas classic bulky (diameter > 10 cm) was detected in 99 (33%; subgroup C). Two hundred eighty patients (88%) showed a postchemotherapy RM. The median dose of cRT was 30.6 Gy (range, 24-36 Gy). After a median follow-up of 5.9 years (range, 0.5-10 years), the 6-year progression-free survival rate of patients who underwent cRT or NFT was, respectively, 91% (95% CI, 84% to 99%) and 95% (95% CI, 89% to 100%; P = .62) in subgroup A; 98% (95% CI, 93% to 100%) and 90% (95% CI, 80% to 100%; P = .24) in subgroup B; 89% (95% CI, 81% to 98%) and 86% (95% CI, 77% to 96%; P = .53) in subgroup C (classic bulky). CONCLUSION: cRT could be safely omitted in patients with HL presenting with an LNM and a negative PET-2 and PET-6 scan, irrespective from the LNM size detected at baseline.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Gallamini A, Rossi A, Patti C, et al. Consolidation Radiotherapy Could Be Safely Omitted in Advanced Hodgkin Lymphoma With Large Nodal Mass in Complete Metabolic Response After ABVD: Final Analysis of the Randomized GITIL/FIL HD0607 Trial. J Clin Oncol. 2020. PMID: 32946355. doi:10.1200/JCO.20.00935

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。